-
1Academic Journal
Authors: I. M. Patrikeeva, Yu. A. Lushpaeva, N. V. Knaub, E. A. Ustinova, O. A. Belikov, M. B. Dolgikh, T. Yu. Malysheva, И. М. Патрикеева, Ю. А. Лушпаева, Н. В. Кнауб, Е. А. Устинова, О. А. Беликов, М. Б. Долгих, Т. Ю. Малышева
Source: Modern Rheumatology Journal; Том 19, № 1 (2025); 57-63 ; Современная ревматология; Том 19, № 1 (2025); 57-63 ; 2310-158X ; 1996-7012
Subject Terms: гуманизированное моноклональное антитело, olokizumab, interleukin-6 inhibitor, humanized monoclonal antibody, олокизумаб, ингибитор интерлейкина 6
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1703/1559; Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. doi:10.1038/ni.3153.; Kondo N, Kuroda T, Kobayashi D. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis. Int J Mol Sci. 2021 Oct 10;22(20):10922. doi:10.3390/ijms222010922.; Pandolfi F, Franza L, Carusi V, et al. Interleukin-6 in Rheumatoid Arthritis. Int J Mol Sci. 2020 Jul 23;21(15):5238. doi:10.3390/ijms21155238.; Kishimoto T, Kang S. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol. 2022 Apr 26;40:323-348. doi:10.1146/annurev-immunol-101220-023458. Epub 2022 Feb 3.; Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii43-ii50. doi:10.1093/rheumatology/kex513.; Taylor PC, Fautrel B, Piette Y, et al. Treat-to-target in rheumatoid arthritis: a realworld study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD Open. 2022 Dec;8(2):e002658. doi:10.1136/rmdopen-2022-002658.; Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575-84. doi:10.1007/s12272-015-0569-8. Epub 2015 Feb 4.; Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17): 1865-1879. doi:10.1007/s40265-017-0829-7.; Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Mod Rheumatol. 2019 Mar;29(2):258-267. doi:10.1080/14397595.2018.1546357. Epub 2019 Jan 3.; Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs. 2024 Jan;38(1):61-71. doi:10.1007/s40259-023-00634-1. Epub 2023 Nov 21.; Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Apr; 81(4):469-479. doi:10.1136/annrheumdis2021-219876. Epub 2021 Aug 3.; Smolen JS, Feist E, Fatenejad S, et al; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi:10.1056/NEJMoa2201302.; Feist E, Fleischmann RM, Fatenejad S и др. Комбинация олокизумаба с метотрексатом: безопасность и эффективность за 106 недель терапии. Современная ревматология. 2024;18(6):21-35. doi:10.14412/1996-7012-2024-6-21-35; Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi:10.1136/ard.2010.138461.; Smolen, Josef S, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi:10.1136/ard-2022-223356. Epub 2022 Nov 10.; Van der Heijde D. Structural damage in rheumatoid arthritis as visualized through radiographs. Arthritis Res. 2002;4 Suppl 2 (Suppl 2):S29-33. doi:10.1186/ar550. Epub 2002 Mar 27.; Каратеев ДЕ, Степанова ЕА, Лучихина ЕЛ. Методические рекомендации по рентгенологическим методам исследования при ревматоидном артрите и анкилозирующем спондилите. Эффективная фармакотерапия. 2022;18(18):12-25.; Федеральные клинические рекомендации по диагностике и лечению ревматоидного артрита. 2021. https://cr.minzdrav.gov.ru/recomend/250_2; Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013 May 4;381(9877):1541-50. doi:10.1016/S0140-6736(13)60250-0. Epub 2013 Mar; Su QY, Luo J, Zhang Y, et al. Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis. J Transl Med. 2024 Aug 28;22(1):795. doi:10.1186/s12967-024-05569-x.; Моисеев СВ, Новиков ПИ, Чеботарева НВ и др. Олокизумаб в лечении ревматоидного артрита. Клиническая фармакология и терапия. 2021;30(2):67-74.; Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi:10.1002/cpdd.121. Epub 2014 May 26.; Yip RML, Yim CW. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. J Clin Rheumatol. 2021 Dec 1;27(8): e516-e524. doi:10.1097/RHU.0000000 000001293.; Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019 Aug 1;5(2): e000887. doi:10.1136/rmdopen-2018-000887.
-
2Academic Journal
Authors: Bakulev A.I., Samtsov A.V., Sokolovskiy E.V., Kokhan M.M., Khobeish M.M., Khairutdinov V.R., Karamova A.E., Olisova O.U., Ignatiev D.V., Nikiforova A.N., Artemeva A.V., Zinkina-Orikhan A.V.
Contributors: Sponsorship for this study was funded by JSC BIOCAD., Спонсором клинического исследования BCD-085-7/PLANETA является ЗАО «БИОКАД».
Source: Vestnik dermatologii i venerologii; Vol 98, No 2 (2022); 42-52 ; Вестник дерматологии и венерологии; Vol 98, No 2 (2022); 42-52 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.982
Subject Terms: netakimab, psoriasis, humanized monoclonal antibody, adverse events, нетакимаб, псориаз, гуманизированное моноклональное антитело, нежелательные явления
File Description: application/pdf
Relation: https://vestnikdv.ru/jour/article/view/1306/pdf; https://vestnikdv.ru/jour/article/view/1306/pdf_1; https://vestnikdv.ru/jour/article/downloadSuppFile/1306/1065; https://vestnikdv.ru/jour/article/downloadSuppFile/1306/1066; https://vestnikdv.ru/jour/article/downloadSuppFile/1306/1067; https://vestnikdv.ru/jour/article/view/1306
-
3Academic Journal
Authors: S. K. Zyryanov, O. I. Butranova, С. К. Зырянов, О. И. Бутранова
Source: PULMONOLOGIYA; Том 28, № 5 (2018); 584-601 ; Пульмонология; Том 28, № 5 (2018); 584-601 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-5
Subject Terms: февипипрант, phenotypes of bronchial asthma, genetically engineered drugs, humanized monoclonal antibodies, omalizumab, quilizumab, ligelizumab, lebrikizumab, tralokinumab, dupilumab, mepolizumab, benralizumab, fevipiprant, фенотипы бронхиальной астмы, генно-инженерно-биологические препараты, гуманизированное моноклональное антитело, омализумаб, квилизумаб, лигелизумаб, лебрикизумаб, тралокинумаб, дупилумаб, меполизумаб, бенрализумаб
File Description: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/1058/867; Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21 (123): 66–74. DOI:10.1183/09059180.00008111.; Desai M., Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann. Allergy Asthma Immunol. 2016; 116 (5): 394–401. DOI:10.1016/j.anai.2015.12.024.; Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18 (5): 716–725. DOI:10.1038/nm.2678.; Menzella F., Galeone C., Bertolini F. et al. Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017; (10): 237–247. DOI:10.2147/JAA.S144100.; Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137 (6): 1631–1645. DOI:10.1016/j.jaci.2016.04.009.; Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60 (3): 302–308. DOI:10.1111/j.1398-9995.2004.00770.x.; Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309–316. DOI:10.1111/j.1398-9995.2004.00772.x.; Brusselle G., Michils A., Louis R. et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med. 2009; 103 (11):1633–1642. DOI:10.1016/j.rmed.2009.06.014.; Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107 (8) 1141–1151. DOI:10.1016/j.rmed.2013.04.017.; Milgrom H., Berger W., Nayak A. et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108 (2): e36. DOI:10.1542/peds.108.2.e36.; Busse W.W., Morgan W.J., Gergen P.J. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 2011; 364 (11): 1005–1015. DOI:10.1056/NEJMoa1009705.; Brodlie M., McKean M.C., Moss S., Spencer D.A. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch. Dis. Child. 2012; 97 (7): 604–609. DOI:10.1136/archdischild-2011-301570.; Odajima H., Ebisawa M., Nagakura T. et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol. Int. 2015; 64 (4): 364–370. DOI:10.1016/j.alit.2015.05.006.; Odajima H., Ebisawa M., Nagakura T. et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol. Int. 2017; 66 (1): 106–115. DOI:10.1016/j.alit.2016.06.004.; Deschildre A., Marguet C., Salleron J. et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur. Respir. J. 2013; 42 (5): 1224–1233. DOI:10.1183/09031936.00149812.; Deschildre A., Marguet C., Langlois C. et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur. Respir. J. 2015; 46 (3): 856–859. DOI:10.1183/09031936.00008115.; Campbell J.M., Wofford J.D., Knutsen A.P. Omalizumab treatment in children 6 to 18 years old with severe asthma at a children’s medical center. Pediatr. Allergy Immunol. Pulmonol. 2008; 21 (3): 123–148. DOI:10.1089/pai.2008.0502.; Corren J., Kavati A., Ortiz B. et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017; 38 (4): 250–263. DOI:10.2500/aap.2017.38.4067.; Lanier B., Bridges T., Kulus M. et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin. Immunol. 2009; 124 (6): 1210–1216. DOI:10.1016/j.jaci.2009.09.021.; Steiss J.O., Schmidt A., Nährlich L. et al. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc. 2012; 33 (1): 77–81. DOI:10.2500/aap.2012.33.3500.; Mansur A., Srivastava S., Mitchell V. et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir. Med. 2017; 124: 36–43. DOI:10.1016/j.rmed.2017.01.008.; Long A., Rahmaoui A., Rothman K.J. et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J. Allergy Clin. Immunol. 2014; 134 (3): 560–567. DOI:10.1016/j.jaci.2014.02.007.; Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016; (17): 29. DOI:10.1186/s12931-016-0347-2.; Hanania N.A., Alpan O., Hamilos D.L. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 2011; 154 (9): 573–582. DOI:10.7326/0003-4819-154-9-201105030-00002.; Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138 (4): 1051-1059. DOI:10.1016/j.jaci.2016.02.027.; Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 (8) 748–756. DOI:10.1136/thoraxjnl-2014-206719.; Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44 (1): 38–46. DOI:10.1111/cea.12220.; Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4 (10): 781–796. DOI:10.1016/S2213-2600(16)30265-X.; Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10 (6): 473–490. DOI:10.2217/imt-2017-0191.; Simpson E.L., Flohr C., Eichenfield L.F. et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J. Am. Acad. Dermatol. 2018; 78 (5): 863–871. DOI:10.1016/j.jaad.2018.01.017.; Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130 (2): 516–522. DOI:10.1016/j.jaci.2012.03.030.; Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 (10): 1115–1121. DOI:10.1007/s40265-017-0768-3.; Gooderham M.J., Hong H.C., Eshtiaghi P., Papp K.A. Dupilumab: a review of its use in the treatment of atopic dermatitis. J. Am. Acad. Dermatol. 2018; 78 (3, Suppl.1): S28–S36. DOI:10.1016/j.jaad.2017.12.022.; Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI:10.1016/S0140-6736(12)60988-X.; Varricchi G., Senna G., Loffredo S. et al. Reslizumab and eosinophilic asthma: one step closer to precision medicine? Front Immunol. 2017; (8): 242. DOI:10.3389/fimmu.2017.00242.; Garcia G., Taille C., Laveneziana P. et al. Anti-interleukin-5 therapy in severe asthma. Eur. Respir. Rev. 2013; 22 (129): 251–257. DOI:10.1183/09059180.00004013.; Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1198–207. DOI:10.1056/NEJMoa1403290.; Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11 (1): 40–45. DOI:10.1177/1753465816673303.; Menzies-Gow A., Flood-Page P., Sehmi R. et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 2003; 111 (4): 714–719. DOI:10.1067/mai.2003.1382.; Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003; 167 (2): 199–204. DOI:10.1164/rccm.200208-789OC.; Flood-Page P., Swenson C., Faiferman I. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 2007; 176 (11): 1062–1071. DOI:10.1164/rccm.200701-085OC.; Haldar P., Brightling C. E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360 (10): 973–984. DOI:10.1056/NEJMoa0808991.; Nair P., Pizzichini M.M., Kjarsgaard M. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009; 360 (10): 985–993. DOI:10.1056/NEJMoa0805435.; Bel E.H., Wenzel S.E., Thompson P.J. et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1189–1197. DOI:10.1056/NEJMoa1403291.; Haldar P., Brightling C.E., Singapuri A. et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J. Allergy Clin. Immunol. 2014; 133 (3): 921–923. DOI:10.1016/j.jaci.2013.11.026.; Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070. DOI:10.1016/j.clinthera.2016.07.010.; Chupp G.L., Bradford E.S., Albers F.C. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir. Med. 2017; 5 (5): 390–400. DOI:10.1016/S2213-2600(17)30125-X.; Yancey S.W., Ortega H.G., Keene O.N. et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J. Allergy Clin. Immunol. 2017; 139 (4): 1167–1175. DOI:10.1016/j.jaci.2016.08.008.; Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011; 184 (10): 1125–1132. DOI:10.1164/rccm.201103-0396OC.; Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI:10.1016/S2213-2600(15)00042-9.; Bjermer L., Lemiere C., Maspero J. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016; 150 (4): 789–798. DOI:10.1016/j.chest.2016.03.032.; Corren J., Weinstein S., Janka L. et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016; 150 (4): 799–810. DOI:10.1016/j.chest.2016.03.018.; Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12: 619–628. DOI:10.2147/DDDT.S155307.; Busse W.W., Katial R., Gossage D. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010; 125 (6):1237–1244 e2. DOI:10.1016/j.jaci.2010.04.005.; Laviolette M., Gossage D.L., Gauvreau G. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 2013; 132 (5): 1086–1096 e5. DOI:10.1016/j.jaci.2013.05.020.; Park H.S., Kim M.K., Imai N. et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int. Arch. Allergy Immunol. 2016; 169 (3): 135–145. DOI:10.1159/000444799.; Castro M., Wenzel S.E., Bleecker E.R. et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2014; 2 (11): 879–890. DOI:10.1016/S2213-2600(14)70201-2.; Nowak R.M., Parker J.M., Silverman R.A. et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am. J. Emerg. Med. 2015; 33 (1): 14–20. DOI:10.1016/j.ajem.2014.09.036.; Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI:10.1016/S0140-6736(16)31324-1.; FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI:10.1016/S0140-6736(16)31322-8.; Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448–2458. DOI:10.1056/NEJMoa1703501.; Ferguson G.T., FitzGerald J.M., Bleecker E.R. et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2017; 5 (7): 568–576. DOI:10.1016/S2213-2600(17)30190-X.; Matera M.G., Calzetta L., Rinaldi B., Cazzola M. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin. Drug Metab. Toxicol. 2017; 13 (9): 1007–1013. DOI:10.1080/17425255.2017.1359253.; Liu T., Wang F., Wang G. et al. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018; 12 (3): 340–349. DOI:10.1007/s11684-017-0565-0.; FitzGerald J.M., Bleecker E.R., Menzies-Gow A. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 2018; 6 (1): 51–64. DOI:10.1016/S2213-2600(17)30344-2.; Chipps B.E., Newbold P., Hirsch I. et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann. Allergy Asthma Immunol. 2018; 120 (5): 504–511. DOI:10.1016/j.anai.2018.01.030.; Albers F.C., Müllerová H., Gunsoy N.B. et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma. 2017; 55 (2): 152–160. DOI:10.1080/02770903.2017.1322611.; Albers F.C., Liu M.C., Chipps B.E. et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomes. J. Allergy Clin. Immunol. 2018; 141 (2): AB408. DOI:10.1016/j.jaci.2017.12.964.; Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016; (39): 54–63. DOI:10.1016/j.pupt.2016.06.005.; Gonem S., Berair R., Singapuri A. et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: single-centre, randomised, double-blind, parallel-group, placebo controlled trial. Lancet Respir. Med. 2016; 4 (9): 699–707. DOI:10.1016/S2213-2600(16)30179-5.; Bateman E.D., Guerreros A.G., Brockhaus F. et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur. Respir. J. 2017: 50 (2): pii: 1700670. DOI:10.1183/13993003.00670-2017.; https://journal.pulmonology.ru/pulm/article/view/1058
-
4Academic Journal
Authors: Zyryanov S.K., Butranova O.I.
Source: Pulmonologiya
Subject Terms: Benralizumab, Bronchial asthma, Dupilumab, Fevipiprant, Genetically engineered drugs, Humanized monoclonal antibodies, Lebrikizumab, Ligelizumab, Mepolizumab, Omalizumab, Phenotypes of bronchial asthma, Quilizumab, Tralokinumab, бронхиальная астма, фенотипы бронхиальной астмы, генно-инженерно-биологические препараты, гуманизированное моноклональное антитело, омализумаб, квилизумаб, лигелизумаб, лебрикизумаб, тралокинумаб, дупилумаб, меполизумаб, бенрализумаб, февипипрант
Relation: https://doi.org/10.18093/0869-0189-2018-28-5-584-601; https://repository.rudn.ru/records/article/record/36450/
Availability: https://repository.rudn.ru/records/article/record/36450/